1. Introduction

Dasatinib (brand name Sprycel) is a second-generation, reversible tyrosine kinase inhibitor (TKI) primarily used in the management of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its development was driven by the need for agents effective against imatinib-resistant CML, particularly in cases harboring BCR-ABL kinase domain mutations or resistance mechanisms involving alternative signaling pathways.

2. Mechanism of Action

Dasatinib exerts its anticancer effects through broad inhibition of multiple receptor and non-receptor tyrosine kinases at nanomolar concentrations:

• BCR-ABL (Breakpoint Cluster Region–Abelson murine leukemia viral oncogene homolog)
  • Primary target in CML; critical for leukemic cell proliferation.
• SRC family kinases (SRC, LCK, YES, FYN)
• c-KIT
• EPHA2
• PDGFR (Platelet-Derived Growth Factor Receptor)

Dasatinib binds to the ATP-binding site of these kinases in multiple conformations, leading to inhibition of downstream signaling pathways such as RAS/MAPK and PI3K/AKT, which are implicated in cell survival, proliferation, and resistance.

Evidence Base:
Multiple in vitro studies demonstrate dasatinib’s efficacy against both imatinib-sensitive and -resistant CML cell lines (Chang et al., 2004; Zhang et al., 2010). It overcomes resistance conferred by BCR-ABL mutations (T315I, Y253H), SRC family activation (e.g., LYN, HCK), and multidrug resistance gene overexpression.

3. Clinical Indications

• First-line therapy for Ph+ CML in chronic phase
• Treatment of Ph+ ALL in patients with blast phase or transformation
• Second-line/third-line option after failure of prior TKIs (e.g., imatinib)

Guideline Support:
NCCN and ESMO guidelines recommend dasatinib as an alternative first-line agent for patients intolerant to or resistant to imatinib, especially in those with BCR-ABL-positive disease (NCCN Guidelines v.2024).

4. Dosage Regimens

Adults

• CML, Chronic Phase: 100 mg PO once daily
• CML Blast/Myeloid or Lymphoid Blast Phase, Ph+ ALL: 140 mg PO once daily

Pediatrics

Administration:
Tablets must be taken whole; do not crush or chew. Accidental breakage requires use of gloves to prevent dermal exposure due to potential toxicity and sensitization risk.

5. Pharmacokinetics & Drug Interactions

• Absorption: Good oral bioavailability (~80%)
• Metabolism: Primarily via CYP3A4
• Excretion: Renal and fecal

Significant Drug Interactions:

• CYP3A4 inhibitors: Dronedarone, fluconazole, clarithromycin, ritonavir (can increase dasatinib levels → risk of toxicity)
• CYP3A4 inducers: Rifampin, carbamazepine, phenytoin (may decrease efficacy)
• Other: Avoid live vaccines (e.g., measles, mumps, rubella, varicella) due to immunosuppression; avoid with other potent TKIs or QT-prolonging agents.

Clinical Insight:
Pharmacists should review all concomitant medications for CYP3A4 interactions and advise dose adjustments or alternative therapies as needed.

6. Adverse Effects & Monitoring

Common Side Effects

• Headache
• Flu-like symptoms
• Mild rash
• Mouth ulcers
• Weakness, fatigue
• Weight loss
• Peripheral edema
• Abdominal pain, nausea, vomiting, diarrhea
• Peripheral neuropathy (weakness, sensory changes)
• Myalgia, arthralgia

Serious Adverse Effects

• QT Prolongation: Dasatinib can prolong QT interval; monitor in patients with cardiac risk factors or concurrent QT-prolonging drugs.
• Hepatotoxicity: Transaminase elevations common; baseline and periodic monitoring required.
• Pulmonary Toxicity: Rare but serious interstitial lung disease.
• Fluid Retention: Pleural/pericardial effusion, peripheral edema—promptly report symptoms of dyspnea or swelling.

Monitoring Recommendations:

• Baseline and periodic CBC, LFTs, renal function
• ECG for QT interval assessment if risk factors present
• Monitor for signs/symptoms of pulmonary/pleural effusion

7. Special Populations

Pregnancy & Lactation

• Contraindicated: Dasatinib is teratogenic; risk of fetal death, major malformations (neural tube defects), hydrops fetalis, and thrombocytopenia.
• Counsel women of reproductive potential to use effective contraception.
• Breastfeeding: Not recommended during therapy or for 2 weeks post-discontinuation due to risk of infant exposure.

Pediatrics

• Dosing based on weight; careful titration in younger children.

8. Storage & Handling

• Store at 20–25°C (68–77°F), protected from moisture and light.
• Keep out of reach of children.

9. Summary for Pharmacists

Dasatinib is a potent, broad-spectrum TKI with proven efficacy in imatinib-resistant/intolerant Ph+ CML and Ph+ ALL. Pharmacists play a critical role in:

• Ensuring correct dosing based on weight and disease phase
• Monitoring for adverse effects (especially QT prolongation, hepatotoxicity, pulmonary symptoms)
• Managing drug interactions, particularly with CYP3A4 modulators
• Counseling patients on pregnancy prevention, infection risk, and safe handling of medication

Evidence-based practice: Adherence to NCCN/ESMO guidelines, vigilant monitoring, and patient education are essential for optimizing outcomes and minimizing toxicity.

References:

1. NCCN Guidelines v.2024: Chronic Myeloid Leukemia.
2. ESMO Clinical Practice Guidelines (2023).
3. Chang et al., Blood 2004; Zhang et al., J Clin Oncol 2010.
4. FDA Prescribing Information for Sprycel (dasatinib).
5. Lexicomp, Micromedex, UpToDate.